Rifampicin resistance phenotyping of Brucella melitensis by rpoB gene analysis in clinical isolates

Journal of Chemotherapy

Volumn 20, Issue 4, 2008, Pages 431-435

  Sayan, Murat ^a   Yumuk, Z ^a   Dundar D ^a   Bilenoglu O ^b   Erdenlig S ^c   Yasar E ^d   Willke, A ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b Meridyen Is Merkezi   (Turkey)

^c Pendik Veteriner Kontrol ve Arastirma Enstitusu   (Turkey)

^d Clinical Microbiology Laboratory   (Turkey)

Author keywords

Brucella melitensis; Rifampicin resistance; rpoB gene; SNP analysis

Indexed keywords

ADENOSINE; CYTOSINE; GUANINE; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; THYMINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BRUCELLA MELITENSIS; CONTROLLED STUDY; EPSILOMETER TEST; GENE MUTATION; GENE SEQUENCE; GENOME ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TURKEY (REPUBLIC);

EID: 52249120553     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.4.431     Document Type: Article

References (32)

1. Refai M. Incidence and control of brucellosis in the near east region. Vet Microbiol 2002; 90: 81-110.
2. Bodur H, Balaban N, Aksaray S, et al. Short communication. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis 2003; 35:337-338.
3. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis 2006; 6: 91-99.
4. Le Flèche P, Jacques I, Grayon M, et al. Research article. Evaluation and selection of tandem repeat loci for a Brucella MLVA typing assay. BMC Microbiol 2006; 6: 1-14.
5. Del Vecchio VG, Kapatral V, Redkar RJ, et al. The genome sequence of the facultative intracellular pathogen Brucella melitensis. P Natl Acad Sci USA 2002; 99: 443-448.
6. Yüce A, Çavuş SA. Brucellosis in Turkey. A review. Klimik Derg 2006; 19:87-97.
7. Şimşek H, Erdenliǧ S, Oral B, Tülek N. Typing-biotyping of Brucella isolates of human origin and their epidemiologic evaluation. Klimik Derg 2004; 17:103-106.
8. Köse Ş, Kiliç S, Özbel Y. Identification of Brucella species isolated from proven brucellosis patients in Izmir, Turkey. J Basic Microb 2005; 45:323-327.
9. Gür A, Geyik MF, Dikici B, et al. Complications of brucellosis in different age groups: a study of 283 cases in southeastern Anatolia of Turkey. Yonsei Med J 2003; 44: 33-44.
10. Martin IT, Sanchez EG, Fresnadillo MJ, Sanchez JEG, Rodriguez JAG. Correspondence. In vitro activities of five new antimicrobial agents against Brucella melitensis. Int J Antimicrob Ag 1999; 12:185-186.
11. Yumuk Z, Dündar V. The effect of long-term ethanol feeding on efficacy of doxycycline plus rifampicin in the treatment of experimental brucellosis caused by Brucella melitensis in rats. J Chemother 2005;17(5):509-13.
12. Çavasoglu C, Hilmioglu S, Guneri S, Bilgiç A. Characterization of rpoB mutations in rifampicin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J Clin Microbiol 2002; 40:4435-4438.
13. Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001;104:901-912.
14. Merino AL, Rodriguez AC, Ortiz RM, et al. Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scan J Infect Dis 2004; 36: 636-638.
15. Gür D, Kocagöz S, Akova M, Ünal S. Comparison of E Test to microdilution for determining in vitro activities of antibiotics against Brucella mellitensis. Antimicrob Agents Ch 1999; 43(9): 2337.
16. Marianelli C, Ciuchini F, Tarantino M, Pasquali P, and Adone R. Genetic bases of the rifampicin resistance phenotype in Brucella spp. J Clin Microbiol 2004; 42(12):5439-5443.
17. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC, eds. Color Atlas and Textbook of Diagnostic Microbiology. 5th ed. Lippincott Philadelphia-New York, 1997; 434-436.
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI document 2006; 26(3): M100-S16.
19. Baykam N, Esener H, Ergönül Ö, Eren S, Çlikbas AK, Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Ag 2004; 23:405-407.
20. Eşel D, Sümerkan B, Ayangil D, Telli M. Comparison of agar dilution method and E Test in the determination of antibiotic susceptibility of Brucella melitensis strains. ANKEM Derg 2004;18(4):196-199.
21. Turkmani A, Ioannidis A, Christidou A, Psaroulaki A, Loukaides F, Tselentis Y. In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics. Ann Clin Microbiol Antimicrob 2006; 5(24):1-4.
22. Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by E Test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J CIin Microbiol 2005; 43(1): 140-143.
23. Garibyan L, Huang T, Kim M, et al. Use of the rpoB gene to determine the specificity of base substitution mutations on the Escherichia coli chromosome. DNA Repair 2003; 2:593-608.
24. Severinov K, Soushko M, Goldfarb A, Nikiforov V. Rifampicin region revisited. New rifampicin-resistant and streptolydigin-resistant mutants in the beta subunit of Escherichia coli RNA polymerase. J Biol Chem 1993; 268: 14820-14825.
25. Williams DL, Waguespack C, Eisenach K, et al. Characterization of rifampicin resistance in pathogenic mycobacteria. Antimicrob Agents Chemother 1994; 38: 2380-2386.
26. Ohno H, Koga H, Kohno S, Tashiro I, Hara K. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Ch 1996; 40: 1053-1056.
27. Nielsen K, Hindersson P, Hoiby N, Bangsborg JM. Sequencing of the rpoB gene in Legionella pneumophila and characterization of mutations associated with rifampin resistance in the Legionellaceae. Antimicrob Agents Chemother 2000; 44(10): 2679-2683.
28. Heep M, Beck D, Bayerdörffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Ch 1999; 43(6): 1497-1499.
29. Oǧuz AV, Eroǧlu C, Güneri S, et al. RpoB gene mutations in rifampicin-resistant Mycobacterium tuberculosis strains isolated in the Aegean region of Turkey. J Chemother 2004; 16(5): 442-5.
30. Karahan ZC, Atalay, F Uzun M, Erturan Z, Atasever M, Akar N. Sequence analysis of rpoB mutations in rifampicin-resistant clinical Mycobacterium tuberculosis isolates from Turkey. Microb Drug Resist 2004; 10 (4): 325-333.
31. Kocabaş A. Pulmonary tuberculosis. In: Willke TA, Söyletir G, Doǧanay M, eds. Infectious Diseases and Microbiology. Istanbul: Nobel Tip Kitabevleri Pres. 2002; 38-591.
32. Pappas G, Solera J, Akritidis N, Tsianos E. Review. New approaches to the antibiotic treatment of brucellosis. Int. J. Antimicob Agents 2005; 26: 101-105.